Logo

QGEN

Qiagen N.V.

QGEN

Qiagen N.V. • NYSE
$47.75 ▼ -0.73% (-0.35)
Market Cap $10.35 B
52w High $51.88
52w Low $37.63
Dividend Yield 0.25%
P/E 25.81
Volume 302.03K
Outstanding Shares 216.83M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $532.583M ▼ $202.096M ▼ $130.043M ▲ 24.417% ▲ $0.6 ▲ $277.236M ▲
Q2-2025 $533.54M ▲ $212.384M ▲ $96.25M ▲ 18.04% ▼ $0.44 ▲ $183.904M ▲
Q1-2025 $483.456M ▼ $193.334M ▼ $90.758M ▲ 18.773% ▲ $0.42 ▲ $170.751M ▼
Q4-2024 $521.202M ▲ $214.192M ▲ $88.322M ▼ 16.946% ▼ $0.41 ▼ $182.547M ▲
Q3-2024 $501.869M $196.204M $98.056M 19.538% $0.44 $177.933M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.69B ▲ $6.553B ▲ $2.904B ▲ $3.649B ▲
Q2-2025 $953.815M ▼ $5.824B ▲ $2.318B ▲ $3.505B ▲
Q1-2025 $963.445M ▼ $5.545B ▼ $2.137B ▲ $3.408B ▼
Q4-2024 $1.153B ▼ $5.69B ▼ $2.122B ▼ $3.567B ▲
Q3-2024 $1.48B $6.27B $2.74B $3.53B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $130.043M ▲ $165.019M ▲ $-156.897M ▼ $614.069M ▲ $621.779M ▲ $118.974M ▼
Q2-2025 $96.25M ▲ $161.435M ▲ $-41.997M ▼ $-27.994M ▲ $95.059M ▲ $120.599M ▲
Q1-2025 $90.758M ▲ $139.74M ▼ $120.081M ▲ $-286.704M ▲ $-24.799M ▲ $95.838M ▼
Q4-2024 $88.322M ▼ $191.509M ▲ $-6.785M ▲ $-488.976M ▼ $-309.43M ▼ $141.853M ▲
Q3-2024 $98.056M $182.347M $-231.038M $485.55M $439.341M $138.031M

Five-Year Company Overview

Income Statement

Income Statement Qiagen’s revenue has leveled off after a pandemic-era surge and now looks relatively stable, but profitability has clearly come down from its peak. Gross margins have tightened, and operating and net income are meaningfully lower than a few years ago. The business remains profitable, just on slimmer margins. This reflects a mix shift away from COVID-related demand, ongoing investment in growth areas, and likely some cost pressure. The overall picture is one of a solid, steady top line but a company still working through a reset in earnings power post-pandemic.

Balance Sheet

Balance Sheet The balance sheet looks generally solid and conservative. Total assets have been fairly steady, cash on hand has remained healthy, and debt has been nudged down over time rather than increased. Shareholders’ equity has built up, suggesting the company has retained value even as earnings have normalized. Qiagen appears to have a good financial cushion, with no obvious signs of over-leverage or liquidity stress, which supports its ability to keep funding R&D and strategic initiatives.

Cash Flow

Cash Flow Cash generation is a relative strength. Operating cash flow has been consistently positive and, despite weaker accounting profits in recent years, has held up well and even improved recently. Free cash flow has been solid, helped by disciplined and fairly stable investment in capital projects. This means Qiagen is converting a good portion of its business activity into real cash, giving it flexibility to invest in innovation, make acquisitions, or strengthen its balance sheet without relying heavily on new borrowing.

Competitive Edge

Competitive Edge Qiagen sits in an attractive niche across life sciences and molecular diagnostics, with a strong presence in sample preparation, testing, and data analysis. Its “Sample to Insight” offering, large installed base of instruments, and recurring consumables model create sticky customer relationships and a notable competitive moat. The brand is well-established in both research and clinical labs worldwide. At the same time, the company competes with large, well-funded diagnostics and life science tools players and must continually defend share as COVID-related testing fades and budgets shift. Its entrenched workflows and broad product menu help, but competition and pricing pressure remain key ongoing risks.

Innovation and R&D

Innovation and R&D Innovation is clearly at the core of Qiagen’s strategy. The company has leveraged its historic strength in sample preparation into a broad platform that includes syndromic testing (QIAstat-Dx), the TB testing franchise (QuantiFERON), digital PCR (QIAcuity), and bioinformatics (QIAGEN Digital Insights). Looking ahead, a pipeline of new instruments, expanded digital PCR capabilities, AI-enabled software, and oncology and liquid biopsy applications all target higher-growth, higher-value niches. Qiagen is also pruning its portfolio, focusing resources on areas with better long-term returns. The opportunity is meaningful, but execution, regulatory approvals, and adoption rates will determine how much of this innovation pipeline translates into durable revenue and margin improvement.

Summary

Qiagen today looks like a solid, cash-generative diagnostics and life sciences tools company in the middle of a transition. Revenue has normalized after the pandemic boom, and margins have stepped down from prior highs, but the business remains firmly profitable. The balance sheet and cash flows provide a comfortable foundation to keep investing aggressively in new platforms. Its integrated workflow, strong brand, and recurring consumables model support a durable competitive position, though the company still faces intense competition and the challenge of replacing COVID-era volumes with newer, higher-growth offerings. Over the next few years, the key story to watch is whether Qiagen’s innovation pipeline and strategic focus can gradually rebuild earnings strength and margin quality from this lower, but stable, base.

NEWS

November 10, 2025 · 1:30 AM UTC

QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025

Read more

November 4, 2025 · 1:04 PM UTC

QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase

Read more

November 4, 2025 · 1:03 PM UTC

QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions

Read more

October 28, 2025 · 5:05 PM UTC

QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing

Read more

October 13, 2025 · 8:24 AM UTC

QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast

Read more